A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site

Molecular Immunology

Volumn 66, Issue 2, 2015, Pages 364-374

  Li, Liuzhe ^a   Wang, Xiao Hong ^b   Williams, Constance ^a   Volsky, Barbara ^a   Steczko, Olivia ^a,g   Seaman, Michael S ^c   Luthra, Kalpana ^e   Nyambi, Phillipe ^a   Nadas, Arthur ^d   Giudicelli, Véronique ^f   Lefranc, Marie Paule ^f   Zolla Pazner, Susan ^a,b   Gorny, Miroslaw K ^a   Choudhary, Alok ^a   Andrabi, Raiees ^a   Tranguch, Susanne ^a   Ryndak, Michelle ^a  

^a Department of Pathology ^*

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^f UNIV MONTPELLIER   (France)

^g BINGHAMTON UNIVERSITY   (United States)

Author keywords

CD4 binding site; HIV neutralizing antibodies; HIV 1; Human monoclonal antibodies; Somatic mutation; V2 region; V3 region

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; CD4 ANTIGEN; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN BINDING; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOELECTRIC POINT; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; POINT MUTATION; PRIORITY JOURNAL; SOMATIC MUTATION; STATIC ELECTRICITY; VIRUS NEUTRALIZATION; BINDING SITE; BLOOD; CHEMISTRY; GENE EXPRESSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDOMA; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; MUTATION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, CD4; BINDING SITES; GENE EXPRESSION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN VARIABLE REGION; MUTATION; PROTEIN BINDING;

EID: 84928884444     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.04.011     Document Type: Article

References (62)

1. Andrabi R., Williams C., Wang X.H., Li L., Choudhary A.K., Wig N., Biswas A., Luthra K., Nadas A., Seaman M.S., Nyambi P., Zolla-Pazner S., Gorny M.K. Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals. Virology 2013, 439:81-88.
2. Bou-Habib D.C., Roderiquez G., Oravecz T., Berman P.W., Lusso P., Norcross M.A. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 1994, 68:6006-6013.
3. Brochet X., Lefranc M.P., Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008, 36:W503-W508.
4. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., Silacci C., Pinna D., Jarrossay D., Balla-Jhagjhoorsingh S., Willems B., Zekveld M.J., Dreja H., O'Sullivan E., Pade C., Orkin C., Jeffs S.A., Montefiori D.C., Davis D., Weissenhorn W., McKnight A., Heeney J.L., Sallusto F., Sattentau Q.J., Weiss R.A., Lanzavecchia A. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010, 5:e8805.
5. Gigler A., Dorsch S., Hemauer A., Williams C., Kim S., Young N.S., Zolla-Pazner S., Wolf H., Gorny M.K., Modrow S. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J. Virol. 1999, 73:1974-1979.
6. Giudicelli V., Brochet X., Lefranc M.P. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harbor Protoc. 2011, 2011:695-715.
7. Giudicelli V., Lefranc M.P. IMGT/junctionanalysis: IMGT standardized analysis of the V-J and V-D-J junctions of the rearranged immunoglobulins (IG) and T cell receptors (TR). Cold Spring Harbor Protoc. 2011, 2011:716-725.
8. Gorny M.K., Conley A.J., Karwowska S., Buchbinder A., Xu J.Y., Emini E.A., Koenig S., Zolla-Pazner S. Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J. Virol. 1992, 66:7538-7542.
9. Gorny M.K., Mascola J.R., Israel Z.R., VanCott T.C., Williams C., Balfe P., Hioe C., Brodine S., Burda S., Zolla-Pazner S. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. AIDS Res. Hum. Retroviruses 1998, 14:213-221.
10. Gorny M.K., Moore J.P., Conley A.J., Karwowska S., Sodroski J., Williams C., Burda S., Boots L.J., Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of HIV-1. J. Virol. 1994, 68:8312-8320.
11. Gorny M.K., Revesz K., Williams C., Volsky B., Louder M.K., Anyangwe C.A., Krachmarov C.P., Kayman S.C., Pinter A., Nadas A., Nyambi P.N., Mascola J.R., Zolla-Pazner S. The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J. Virol. 2004, 78:2394-2404.
12. Gorny M.K., Sampson J., Li H., Jiang X., Totrov M., Wang X.-H., Williams C., O'Neal T., Volsky B., Li L., Cardozo T., Nyambi P., Zolla-Pazner S., Kong X.-P. Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure. PLoS ONE 2011, 6:e27780.
13. Gorny M.K., VanCott T.C., Hioe C., Israel Z.R., Michael N.L., Conley A.J., Williams C., Kessler J.A., Chigurupati P., Burda S., Zolla-Pazner S. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J. Immunol. 1997, 159:5114-5122.
14. Gorny M.K., VanCott T.C., Williams C., Revesz K., Zolla-Pazner S. Effects of oligomerization on the epitopes of the Human Immunodeficiency Virus Type 1 envelope glycoproteins. Virology 2000, 267:220-228.
15. Gorny M.K., Wang X.H., Williams C., Volsky B., Revesz K., Witover B., Burda S., Urbanski M., Nyambi P., Krachmarov C., Pinter A., Zolla-Pazner S., Nadas A. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 2009, 46:917-926.
16. Gorny M.K., Williams C., Volsky B., Revesz K., Cohen S., Polonis V.R., Honnen W.J., Kayman S.C., Krachmarov C.P., Pinter A., Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize HIV-1 primary isolates from various clades. J. Virol. 2002, 76:9035-9045.
17. Gorny M.K., Williams C., Volsky B., Revesz K., Wang X.H., Burda S., Kimura T., Koning F.A., Nadas A., Anyangwe C., Nyambi P., Krachmarov C., Pinter A., Zolla-Pazner S. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of HIV-1. J. Virol. 2006, 80:6865-6872.
18. Gorny M.K., Xu J.-Y., Gianakakos V., Karwowska S., Williams C., Sheppard H.W., Hanson C.V., Zolla-Pazner S. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:3238-3242.
19. Gorny M.K., Xu J.-Y., Karwowska S., Buchbinder A., Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 1993, 150:635-643.
20. Gottardo R., Bailer R.T., Korber B.T., Gnanakaran S., Phillips J., Shen X., Tomaras G.D., Turk E., Imholte G., Eckler L., Wenschuh H., Zerweck J., Greene K., Gao H., Berman P.W., Francis D., Sinangil F., Lee C., Nitayaphan S., Rerks-Ngarm S., Kaewkungwal J., Pitisuttithum P., Tartaglia J., Robb M.L., Michael N.L., Kim J.H., Zolla-Pazner S., Haynes B.F., Mascola J.R., Self S., Gilbert P., Montefiori D.C. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS ONE 2013, 8:e75665.
21. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M.S., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. New Engl. J. Med. 2012, 366:1275-1286.
22. Hioe C.E., Wrin T., Seaman M.S., Yu X., Wood B., Self S., Williams C., Gorny M.K., Zolla-Pazner S. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS ONE 2010, 5:e10254.
23. Jeffs S.A., Gorny M.K., Williams C., Revesz K., Volsky B., Burda S., Wang X.H., Bandres J., Zolla-Pazner S., Holmes H. Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120. Immunol. Lett. 2001, 79:209-213.
24. Jiang X., Burke V., Totrov M., Williams C., Cardozo T., Gorny M.K., Zolla-Pazner S., Kong X.-P. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat. Struct. Mol. Biol. 2010, 17:955-961.
25. Julien J.P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., Ward A.B., Wilson I.A. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
26. Karwowska S., Gorny M.K., Buchbinder A., Gianakakos V., Williams C., Fuerst T., Zolla-Pazner S. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res. Hum. Retroviruses 1992, 8:1099-1106.
27. Kayman S.C., Wu Z., Revesz K., Chen H., Kopelman R., Pinter A. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J. Virol. 1994, 68:400-410.
28. Kwong P.D., Wyatt R., Sattentau Q.J., Sodroski J., Hendrickson W.A. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 2000, 74:1961-1972.
29. Lefranc M.P. Immunoglobulin and T cell receptor genes: IMGT((R)) and the birth and rise of immunoinformatics. Front. Immunol. 2014, 5:22.
30. Lefranc M.P., Giudicelli V., Duroux P., Jabado-Michaloud J., Folch G., Aouinti S., Carillon E., Duvergey H., Houles A., Paysan-Lafosse T., Hadi-Saljoqi S., Sasorith S., Lefranc G., Kossida S. IMGT(R), the international ImMunoGeneTics information system(R) 25 years on. Nucleic Acids Res. 2015, 43:D413-D422.
31. Li L., Wang X.-H., Banerjee S., Volsky B., Williams C., Virland D., Nadas A., Seaman M.S., Chen X., Spearman P., Zolla-Pazner S., Gorny M.K. Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infecgted subject.e. PLoS ONE 2012, 7:e39534.
32. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79:10108-10125.
33. Liao H.X., Bonsignori M., Alam S.M., McLellan J.S., Tomaras G.D., Moody M.A., Kozink D.M., Hwang K.K., Chen X., Tsao C.Y., Liu P., Lu X., Parks R.J., Montefiori D.C., Ferrari G., Pollara J., Rao M., Peachman K.K., Santra S., Letvin N.L., Karasavvas N., Yang Z.Y., Dai K., Pancera M., Gorman J., Wiehe K., Nicely N.I., Rerks-Ngarm S., Nitayaphan S., Kaewkungwal J., Pitisuttithum P., Tartaglia J., Sinangil F., Kim J.H., Michael N.L., Kepler T.B., Kwong P.D., Mascola J.R., Nabel G.J., Pinter A., Zolla-Pazner S., Haynes B.F. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013, 38:176-186.
34. Liu P., Yates N.L., Shen X., Bonsignori M., Moody M.A., Liao H.X., Fong Y., Alam S.M., Overman R.G., Denny T., Ferrari G., Ochsenbauer C., Kappes J.C., Polonis V.R., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Montefiori D.C., Gilbert P., Michael N.L., Kim J.H., Haynes B.F., Tomaras G.D. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J. Virol. 2013, 87:7828-7836.
35. Lynch R.M., Tran L., Louder M.K., Schmidt S.D., Cohen M., Members C.C.T., Dersimonian R., Euler Z., Gray E.S., Abdool Karim S., Kirchherr J., Montefiori D.C., Sibeko S., Soderberg K., Tomaras G., Yang Z.Y., Nabel G.J., Schuitemaker H., Morris L., Haynes B.F., Mascola J.R. The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 2012, 86:7588-7595.
36. Lyumkis D., Julien J.P., de Val N., Cupo A., Potter C.S., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., Carragher B., Wilson I.A., Ward A.B. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
37. Mbah H.A., Burda S., Gorny M.K., Williams C., Revesz K., Zolla-Pazner S., Nyambi P.N. Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades. J. Virol. 2001, 75:7785-7788.
38. McGuire A.T., Dreyer A.M., Carbonetti S., Lippy A., Glenn J., Scheid J.F., Mouquet H., Stamatatos L. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 2014, 346:1380-1383.
39. Montefiori D.C., Karnasuta C., Huang Y., Ahmed H., Gilbert P., de Souza M.S., McLinden R., Tovanabutra S., Laurence-Chenine A., Sanders-Buell E., Moody M.A., Bonsignori M., Ochsenbauer C., Kappes J., Tang H., Greene K., Gao H., LaBranche C.C., Andrews C., Polonis V.R., Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Self S.G., Berman P.W., Francis D., Sinangil F., Lee C., Tartaglia J., Robb M.L., Haynes B.F., Michael N.L., Kim J.H. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 2012, 206:431-441.
40. Moody M.A., Yates N.L., Amos J.D., Drinker M.S., Eudailey J.A., Gurley T.C., Marshall D.J., Whitesides J.F., Chen X., Foulger A., Yu J.S., Zhang R., Meyerhoff R.R., Parks R., Scull J.C., Wang L., Vandergrift N.A., Pickeral J., Pollara J., Kelsoe G., Alam S.M., Ferrari G., Montefiori D.C., Voss G., Liao H.X., Tomaras G.D., Haynes B.F. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J. Virol. 2012, 86:7496-7507.
41. Mouquet H., Klein F., Scheid J.F., Warncke M., Pietzsch J., Oliveira T.Y., Velinzon K., Seaman M.S., Nussenzweig M.C. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PloS one 2011, 6:e24078.
42. Nyambi P.N., Gorny M.K., Bastiani L., van der Groen G., Williams C., Zolla-Pazner S. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J. Virol. 1998, 72:9384-9391.
43. Nyambi P.N., Mbah H.A., Burda S., Williams C., Gorny M.K., Nadas A., Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 2000, 74:7096-7107.
44. Pantophlet R., Aguilar-Sino R.O., Wrin T., Cavacini L.A., Burton D.R. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 2007, 364:441-453.
45. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., Kayman S.C. The V1/V2 domain of gp120 is a global regulator of sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 2004, 78:5205-5215.
46. Ramirez Valdez K.P., Kuwata T., Maruta Y., Tanaka K., Alam M., Yoshimura K., Matsushita S. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology 2014, 475C:187-203.
47. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., Ott R.G., Anthony R.M., Zebroski H., Hurley A., Phogat A., Chakrabarti B., Li Y., Connors M., Pereyra F., Walker B.D., Wardemann H., Ho D., Wyatt R.T., Mascola J.R., Ravetch J.V., Nussenzweig M.C. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
48. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., Coffey R.T., Harris L., Wood B., Daniels M.G., Bhattacharya T., Lapedes A., Polonis V.R., McCutchan F.E., Gilbert P.B., Self S.G., Korber B.T., Montefiori D.C., Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010, 84:1439-1452.
49. Thali M., Furman C., Wahren B., Posner M., Ho D.D., Robinson J., Sodroski J. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J. Acquir. Immun. Defic. Syndr. 1992, 5:591-599.
50. Totrov M., Jiang X., Kong X.P., Cohen S., Krachmarov C., Salomon A., Williams C., Seaman M.S., Cardozo T., Gorny M.K., Wang S., Lu S., Pinter A., Zolla-Pazner S. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology 2010, 405:513-523.
51. Upadhyay C., Mayr L.M., Zhang J., Kumar R., Gorny M.K., Nadas A., Zolla-Pazner S., Hioe C.E. Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope. J. Virol. 2014, 88:12853-12865.
52. van Gils M.J., Sanders R.W. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 2013, 435:46-56.
53. Verkoczy L., Kelsoe G., Moody M.A., Haynes B.F. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 2011, 23:383-390.
54. Verrier F., Nadas A., Gorny M.K., Zolla-Pazner S. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J. Virol. 2001, 75:9177-9186.
55. Vogel T., Kurth R., Norley S. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J. Immunol. 1994, 153:1895-1904.
56. West A.P., Scharf L., Scheid J.F., Klein F., Bjorkman P.J., Nussenzweig M.C. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014, 156:633-648.
57. Yousfi Monod M., Giudicelli V., Chaume D., Lefranc M.P. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J Junctions. Bioinformatics 2004, 20(Suppl. 1):i379L 385.
58. Zhong P., Burda S., Urbanski M., Kenfack H., Tongo M., Heyndrickx L., Nanfack A., Shang J., Agyingi L., Zolla-Pazner S., Zekeng L., Nyambi P. HIV Type 1 Group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon. J. Acquir. Immune Defic. Syndr. 2002, 31:495-505.
59. Zolla-Pazner S. A critical question for HIV vaccine development: which antibodies to induce?. Science 2014, 345:167-168.
60. Zolla-Pazner S., deCamp A.C., Cardozo T., Karasavvas N., Gottardo R., Williams C., Morris D.E., Tomaras G., Rao M., Billings E., Berman P., Shen X., Andrews C., O'Connell R.J., Ngauy V., Nitayaphan S., de Souza M., Korber B., Koup R., Bailer R.T., Mascola J.R., Pinter A., Montefiori D., Haynes B.F., Robb M.L., Rerks-Ngarm S., Michael N.L., Gilbert P.B., Kim J.H. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS ONE 2013, 8:e53629.
61. Zolla-Pazner S., Kong X., Jiang X., Cardozo T., Nadas A., Cohen S., Totrov M., Seaman M.S., Wang S., Lu S. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J. Virol. 2011, 85:9887-9898.
62. Zolla-Pazner S., O'Leary J., Burda S., Gorny M.K., Kim M., Mascola J., McCutchan F.E. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J. Virol. 1995, 69:3807-3815.